Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,430 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disease response and patient-reported outcomes among initiators of ixekizumab.
Shahriari M, Harrison RW, Burge R, Lin CY, Malatestinic WN, Goldblum OM, McLean RR, Crabtree MM, O'Brien J, Grace EL, Murage MJ. Shahriari M, et al. Among authors: lin cy. J Dermatolog Treat. 2022 May;33(3):1538-1546. doi: 10.1080/09546634.2020.1853023. Epub 2020 Dec 2. J Dermatolog Treat. 2022. PMID: 33267635
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group. Mease PJ, et al. Among authors: lin cy. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23. Ann Rheum Dis. 2017. PMID: 27553214 Free PMC article. Clinical Trial.
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.
Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Nikaï E, Zhu B, Edson-Heredia E, Carlier H, Lin CY, Goldblum O, Yosipovitch G. Kimball AB, et al. Among authors: lin cy. J Am Acad Dermatol. 2016 Dec;75(6):1156-1161. doi: 10.1016/j.jaad.2016.07.034. Epub 2016 Sep 27. J Am Acad Dermatol. 2016. PMID: 27692498 Clinical Trial.
Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
Malatestinic W, Nordstrom B, Wu JJ, Goldblum O, Solotkin K, Lin CY, Kistler K, Fraeman K, Johnston J, Hawley LL, Sicignano N, Araujo A. Malatestinic W, et al. Among authors: lin cy. J Manag Care Spec Pharm. 2017 Mar;23(3):370-381. doi: 10.18553/jmcp.2017.16367. Epub 2017 Jan 31. J Manag Care Spec Pharm. 2017. PMID: 28230450 Free PMC article.
Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization.
Armstrong AW, Foster SA, Comer BS, Lin CY, Malatestinic W, Burge R, Goldblum O. Armstrong AW, et al. Among authors: lin cy. BMC Dermatol. 2018 Jun 28;18(1):4. doi: 10.1186/s12895-018-0072-2. BMC Dermatol. 2018. PMID: 29954363 Free PMC article.
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies.
Kavanaugh A, Gottlieb A, Morita A, Merola JF, Lin CY, Birt J, Shuler CL, Hufford MM, Thaçi D. Kavanaugh A, et al. Among authors: lin cy. Ann Rheum Dis. 2019 Sep;78(9):1215-1219. doi: 10.1136/annrheumdis-2018-215003. Epub 2019 May 21. Ann Rheum Dis. 2019. PMID: 31113794 Free PMC article. Clinical Trial.
6,430 results